{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:44:19Z","timestamp":1790073859838,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115756","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:55:25Z","timestamp":1757170525000},"page":"115756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"Michiel","family":"van de Sande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8871-9081","authenticated-orcid":false,"given":"Kirsten","family":"van Langevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scharschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laman","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7014-5346","authenticated-orcid":false,"given":"Chinglin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115756_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejca.2025.115756_bib2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"10.1016\/j.ejca.2025.115756_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11912-020-00926-7","article-title":"Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon\u2019s perspective","volume":"22","author":"Bernthal","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2025.115756_bib4","series-title":"World Health Organization classification of tumours of soft tissue and bone","first-page":"100","article-title":"Tenosynovial giant cell tumor, localized type\/diffuse type","author":"de Saint","year":"2013"},{"key":"10.1016\/j.ejca.2025.115756_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.36469\/jheor.2022.33289","article-title":"Surgical treatment patterns, healthcare resource utilization, and economic burden in patients with tenosynovial giant cell tumor who underwent joint surgery in the United States","volume":"9","author":"Lin","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.ejca.2025.115756_bib6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115756_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10197","key":"10.1016\/j.ejca.2025.115756_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2025.115756_bib9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115756_bib10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/medicina60101675","article-title":"Treatment modalities for refractory-recurrent tenosynovial giant cell tumor (TGCT): an update","volume":"60","author":"Dania","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.ejca.2025.115756_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2022.2067040","article-title":"Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches","author":"Spierenburg","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejca.2025.115756_bib12","article-title":"Single-cell RNA-seq analysis reveals aberrant CSF1 expression in disease-causing synovial fibroblasts of pigmented villonodular synovitis","author":"Tang","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejca.2025.115756_bib13","doi-asserted-by":"crossref","unstructured":"Lin C-C. Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors. J Immunother Precis Oncol. no. 4. p. 105\u201314.","DOI":"10.36401\/JIPO-20-32"},{"key":"10.1016\/j.ejca.2025.115756_bib14","doi-asserted-by":"crossref","unstructured":"Mullard A. FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours; 2025. \u3008https:\/\/www.nature.com\/articles\/d41573-025-00045-7\u3009.","DOI":"10.1038\/d41573-025-00045-7"},{"key":"10.1016\/j.ejca.2025.115756_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/14796694.2024.2396227","article-title":"MANEUVER: a phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","author":"Niu","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115756_bib16","unstructured":"Mescheder A, Blay J-Y, LeBoeuf N, Gelderblom H, van de Sande M, et al. A phase III, multi-centre, randomized, double-blind, group comparator trial to assess the safety and efficacy of Emactuzumab vs Placebo in patients with TGCT (TANGENT); 2021 CTOS."},{"key":"10.1016\/j.ejca.2025.115756_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101514","article-title":"Clinical evaluation of colony-stimulating factor 1 receptor inhibitors","volume":"54","author":"Ordentlich","year":"2021","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115756_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajpath.2011.03.029","article-title":"Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury","volume":"179","author":"Radi","year":"2011","journal-title":"Am J Pathol"},{"issue":"598","key":"10.1016\/j.ejca.2025.115756_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd4550","article-title":"Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition","volume":"13","author":"Bissinger","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115756_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrrheum.2013.159","article-title":"Progress in intra-articular therapy","volume":"10","author":"Evans","year":"2014","journal-title":"Nat Rev Rheuma"},{"issue":"ement 1","key":"10.1016\/j.ejca.2025.115756_bib21","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1063-4584(09)60122-9","article-title":"Pharmacokinetics of an antibody following intra-articular and systemic delivery in rodents","volume":"17","author":"Scully","year":"2009","journal-title":"Osteoarthr Cartil"},{"issue":"348","key":"10.1016\/j.ejca.2025.115756_bib22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jconrel.2022.06.015","article-title":"Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics","volume":"348","author":"Siefen","year":"2022","journal-title":"J Control Release"},{"issue":"19","key":"10.1016\/j.ejca.2025.115756_bib23","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-16-3261","article-title":"First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors","volume":"23","author":"Papadopoulos","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115756_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.11048","article-title":"Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: relationship with patient-reported outcomes (PROs)","author":"Peterfy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115756_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jconrel.2021.12.010","article-title":"Intra-articular delivery of full-length antibodies through the use of an in situ forming depot","volume":"341","author":"De Maudave","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.ejca.2025.115756_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giantcell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115756_bib28","doi-asserted-by":"crossref","unstructured":"Blay J-Y, Gelderblom H, Rutkowski P, Wagner AJ, van de Sande M. Efficacy and safety of vimseltinib in tenosynovial giant cell tumor (TGCT): phase 2 expansion; 2022 ESMO 1509P.","DOI":"10.1016\/j.annonc.2022.07.1612"},{"key":"10.1016\/j.ejca.2025.115756_bib29","doi-asserted-by":"crossref","unstructured":"Xu H, Zhou Y, Li B, Xie X, et al. Efficacy and safety profile of pimicotinib (ABSK021) in TGCT; 2023 ASCO 11559.","DOI":"10.1200\/JCO.2023.41.16_suppl.11559"},{"key":"10.1016\/j.ejca.2025.115756_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115756_bib31","first-page":"11500","article-title":"Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: results from the phase 3 MOTION trial","author":"Tap","year":"2024","journal-title":"ASCO"},{"key":"10.1016\/j.ejca.2025.115756_bib32","unstructured":"Pimicotinib significantly improved outcomes for patients with TGCT in phase III trial; 2024. \u3008https:\/\/www.emdgroup.com\/en\/news\/pimicotinib-topline-results-12-11-2024.html\u3009."},{"key":"10.1016\/j.ejca.2025.115756_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1964","article-title":"PK\/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse-type tenosynovial giant cell tumor","author":"Smart","year":"2020","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T06:37:40Z","timestamp":1759214260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"alternative-id":["S0959804925005416"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115756","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115756"}}